Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.47
-0.80 (-7.79%)
At close: May 22, 2026, 4:00 PM EDT
9.61
+0.14 (1.48%)
After-hours: May 22, 2026, 7:07 PM EDT
Telix Pharmaceuticals Revenue
In the year 2025, Telix Pharmaceuticals had annual revenue of $803.79M with 55.61% growth. Telix Pharmaceuticals had revenue of $413.44M in the half year ending December 31, 2025, with 115.29% growth.
Revenue (ttm)
$803.79M
Revenue Growth
+55.61%
P/S Ratio
4.05
Revenue / Employee
$678,880
Employees
1,184
Market Cap
3.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 803.79M | 287.24M | 55.61% |
| Dec 31, 2024 | 516.55M | 183.57M | 55.13% |
| Jan 1, 2024 | 332.98M | 224.17M | 206.01% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.10B |
| Arcus Biosciences | 236.00M |
| Beam Therapeutics | 164.01M |
| Tango Therapeutics | 56.99M |
| Relay Therapeutics | 10.68M |
TLX News
- 4 days ago - Telix Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 4 days ago - Telix Pharmaceuticals Slides: FY 2026 - Filings
- 4 days ago - Telix Pharmaceuticals Transcript: AGM 2026 - Transcripts
- 4 days ago - Telix Pharmaceuticals Slides: FY 2026 - Filings
- 6 days ago - IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing - GlobeNewsWire
- 10 days ago - EDAP Explores Collaboration with Telix Pharmaceuticals on Prostate Cancer Treatments - GuruFocus
- 10 days ago - Telix, EDAP And Profound Partner To Explore PSMA-PET Imaging In Prostate Cancer Treatment - Nasdaq
- 10 days ago - Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches - GlobeNewsWire